Differential expression of NK receptors CD94 and NKG2A by T cells in rheumatoid arthritis patients in remission compared to active disease

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Walsh, Ceara E ^a   Ryan, Elizabeth J ^b   O'Farrelly, Cliona ^b   Golden Mason, Lucy ^b   FitzGerald, Oliver ^a   Veale, Douglas J ^a   Bresnihan, Barry ^a   Fearon, Ursula ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CD158B ANTIGEN; CD161 ANTIGEN; CD57 ANTIGEN; CD69 ANTIGEN; CD94 ANTIGEN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL1; LYMPHOCYTE ANTIGEN; NATURAL KILLER CELL RECEPTOR NKG2A; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; KLRC1 PROTEIN, HUMAN; KLRD1 PROTEIN, HUMAN; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY C; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY D; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CELL ISOLATION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DRUG WITHDRAWAL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MAINTENANCE THERAPY; MALE; NATURAL KILLER CELL; NATURAL KILLER T CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; REMISSION; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; VOLUNTEER; CASE CONTROL STUDY; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; FOLLOW UP; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; MULTICENTER STUDY;

ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY C; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY D; REMISSION INDUCTION; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 81055129665     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027182     Document Type: Article

References (50)

1. Pincus T, O'Dell JR, Kremer JM, (1999) Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy. Ann of Intern Med 131: 768-74.
2. dmann M, Brennan FM, Maini RN, (1996) Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14: 397-440.
3. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, et al. (2006) The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arth Rheum 54: 26-37.
4. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, et al. (2004) Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363: 675-81.
5. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, et al. (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354: 1932-9.
6. Taylor PC, (2003) Anti-TNFalpha therapy for rheumatoid arthritis: an update. Intern Med 42: 15-20.
7. Bansback NJ, Young A, Brennan A, (2005) The NICE reappraisal of biologics in 2005: what rheumatologists need to know. Rheumatology 44: 3-4.
8. Yelin E, Wanke LA, (1999) An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arth Rheum 42: 1209-18.
9. Ollendorf DA, Klingman D, Hazard E, Ray S, (2009) Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population. Clin Ther 31: 825-35.
10. Nuijten MJ, Engelfriet P, Duijn K, Bruijn G, Wierz D, et al. (2001) A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis. Pharmacoeconomics 19: 1051-64.
11. Hyrich KL, Watson KD, Silman AJ, Symmons DP, British Society for Rheumatology Biologics Register (2006) Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology 45: 1558-65.
12. Nam J, Villeneuve E, Emery P, (2009) The role of biomarkers in the management of patients with rheumatoid arthritis. Curr Rheumatol Rep 11: 371-377.
13. Mitsuo A, Morimoto S, Nakiri Y, Suzuki J, Kaneko H, (2006) Decreased CD161+CD8+ T cells in the peripheral blood of patients suffering from rheumatic diseases. Rheumatology 45: 1477-84.
14. Richter J, Benson V, Grobarova V, Svoboda J, Vencovsky J, (2010) CD161 receptor participates in both impairing NK cell cytotoxicity and the response to glycans and vimentin in patients with rheumatoid arthritis. Clin Immunol 136: 139-47.
15. Groh V, Bruhl A, El-Gabalawy H, Nelson JL, Spies T, (2003) Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. Proc Natl Acad Sci USA 100: 9452-7.
16. Armstrong RD, Panayi GS, (1983) Natural killer cell activity in inflammatory joint disease. Clin Rheum 2: 243-9.
17. Seaman WE, (2000) Natural killer cells and natural killer T cells. Arth Rheum 43: 1204-17.
18. Kronenberg M, (2005) Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol 23: 877-900.
19. Yamada H, Kaibara N, Okano S, Maeda T, Shuto T, et al. (2007) Interleukin-15 selectively expands CD57+ CD28- CD4+ T cells, which are increased in active rheumatoid arthritis. Clin Immunol 124: 328-35.
20. Goronzy J, Henel G, Sawai H, Singh K, Lee EB, et al. (2005) Costimulatory pathways in rheumatoid synovitis and T-cell senescence. Ann NY Acad Sci 1062: 182-194.
21. Yen JH, Moore BE, Nakajima T, Scholl D, Schaid DJ, et al. (2001) Major histocompatibility complex class I-recognizing receptors are disease risk genes in rheumatoid arthritis. J Exp Med 193: 1159-1167.
22. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arth Rheum 31: 315-24.
23. Fujiwara S, Akiyama M, Yamakido M, Seyama T, Kobuke K, et al. (1986) Cryopreservation of human lymphocytes for assessment of lymphocyte subsets and natural killer cytotoxicity. J Immunol Methods 90: 265-73.
24. Emery P, Breeveld FC, Hall S, Durez P, Chang DJ, (2008) Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 372: 375-82.
25. Smolen JS, Van der Heijde, St Clair EW, Emery P, Bathon JM, (2006) Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arth Rheum 54: 702-10.
26. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, (2010) Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 69: 631-7.
27. Buch MH, Marzo-Ortega H, Bingham SJ, Emery P, (2004) Long-term treatment of rheumatoid arthritis with tumour necrosis factor alpha blockade: outcome of ceasing and restarting biologicals. Rheumatol 43: 243-4.
28. Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, et al. (2005) Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arth Rheum 52: 27-35.
29. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, et al. (2007) Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 146: 406-15.
30. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, et al. (2005) Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arth Rheum 52: 3381-90.
31. de Matos CT, Berg L, Michaelsson J, Fellander-Tsai L, Karre K, et al. (2007) Activating and inhibitory receptors on synovial fluid natural killer cells of arthritis patients: role of CD94/NKG2A in control of cytokine secretion. Immunol 122: 291-301.
32. Son SW, Kim EO, Ryu ES, Kim TJ, Kim JN, et al. (2009) Upregulation of Fas and downregulation of CD94/NKG2A inhibitory receptors on circulating natural killer cells in patients with new-onset psoriasis. Br J Dermatol 161: 281-8.
33. Leavenworth JW, Schellack C, Kim HJ, Lu L, Spee P, et al. (2010) Analysis of the cellular mechanism underlying inhibition of EAE after treatment with anti-NKG2A F(ab')2. Proc Natl Acad Sci U S A 107: 2562-7.
34. Godfrey DI, Kronenberg M, (2004) Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Invest 114: 1379-88.
35. Maeda T, Yamada H, Nagamine R, Shuto T, Nakashima Y, et al. (2002) Involvement of CD4+,CD57+ T cells in the disease activity of rheumatoid arthritis. Arth Rheum 46: 379-84.
36. Martens PB, Goronzy JJ, Schaid D, Weyand CM, (1997) Expansion of unusual CD4+ T cells in severe rheumatoid arthritis. Arth Rheum 40: 1106-1114.
37. Pawlik A, Ostanek L, Brzosko I, Brzosko M, Masiuk M, et al. (2003) The expansion of CD4+CD28- T cells in patients with rheumatoid arthritis. Arthritis Res Ther 5: 210-213.
38. Warrington KJ, Takemura S, Gorinzy JJ, Weyand CM, (2001) CD4+CD28- T cells in rheumatoid arthritis patients combine features of the innate and adaptive immune systems. Arth Rheum 44: 13-20.
39. Brenchley JM, Karandikar NJ, Betts MR, Ambrozak DR, Hill BJ, et al. (2003) Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood 101: 2711-2720.
40. Cosmi L, De Palma R, Santarlasci V, Maggi L, Capone M, et al. (2008) Human interleukin 17-producing cells originate from a CD161+CD4+ T cell precursor. J Exp Med 205: 1903-1916.
41. Nakajima T, Schulte S, Warrington KJ, Kopecky SL, Frye RL, et al. (2002) T-cell-mediated lysis of endothelial cells in acute coronary syndromes. Circulation 105: 570-575.
42. Rosen DB, Bettadapura J, Alsharifi M, Mathew PA, Warren HS, et al. (2005) Cutting edge: lectin-like transcript-1 is a ligand for the inhibitory human NKR-P1A receptor. J Immunol 175: 7796-7799.
43. Spreu J, Kienie EC, Schrage B, Steinie A, et al. (2007) CLEC2A: a novel, alternatively spliced and skin-associated member of the NKC-encoded AICL-CD69-LLT1 family. Immunogenetics 59: 903-912.
44. Shimamoto M, Ueno Y, Tanaka S, Onitake T, Hanaoka R, et al. (2007) Selective decrease in colonic CD56(+) T and CD161(+) T cells in the inflamed mucosa of patients with ulcerative colitis. World J Gastroenterol 13: 5995-6002.
45. Bovenschen HJ, Langewouters AM, van de Kerkhof PC, (2010) Dimethylfumarate for Psoriasis: Pronounced Effects on Lesional T-Cell Subsets, Epidermal Proliferation and Differentiation, but not on Natural Killer T Cells in Immunohistochemical Study. Am J Clin Dermatol 11: 342-350.
46. Rosen DB, Cao W, Avery DT, Tangye SG, Liu YJ, et al. (2008) Functional consequences of interactions between human NKR-P1A and its ligand LLT1 expressed on activated dendritic cells and B cells. J Immunol 180: 6508-17.
47. Coakley G, Iqbal M, Brooks D, Panayi GS, Lanchbury JS, et al. (2000) CD8+, CD57+ T cells from healthy elderly subjects suppress neutrophil development in vitro: implications for the neutropenia of Felty's and large granular lymphocyte syndromes. Arth Rheum 43: 834-843.
48. Chattopadhyay PK, Betts MR, Price DA, Gostick E, Horton H, et al. (2009) The cytolytic enzymes granyzme A, granzyme B, and perforin: expression patterns, cell distribution, and their relationship to cell maturity and bright CD57 expression. J Leukoc Biol 85: 88-97.
49. Focosi D, Bestagno M, Burrone O, Petrini M, (2010) CD57+ T lymphocytes and functional immune deficiency. J Leukoc Biol 87: 107-16.
50. Gayoso I, Sanchez-Correa B, Campos C, Alonso C, Pera A, et al. (2011) Immunosenescence of human natural killer cell. J Innate Immun 3: 337-343.